干扰素α-2b生物类似药(Center For Genetic Engineering And Biotechnology)(Interferon alfa-2b biosimilar(Center For Genetic Engineering And Biotechnology))

概要

基本信息

药物类型

干扰素、生物类似药

别名

Heberon Alfa R、Inrec

靶点

IFNAR

作用机制

IFNAR激动剂(干扰素α/β受体复合体激动剂)、免疫刺激剂、先天性抗病毒免疫应答诱导剂

治疗领域

感染

在研适应症

病毒感染

非在研适应症-

原研机构

Centro de Ingenieria Genetica y Biotecnologia

在研机构

Heber Biotec SA

非在研机构-

最高研发阶段批准上市

首次获批日期

古巴 (2000-12-01),

病毒感染

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

序列信息

Sequence Code 26333714

当前序列信息引自: *****

关联

14

项与干扰素α-2b生物类似药(Center For Genetic Engineering And Biotechnology) 相关的临床试验

NCT04093323 / Recruiting临床2期IIT

A Phase II Study of Type-1 Polarized Dendritic Cell (aDC1) -Based Treatment in Combination With Tumor-Selective Chemokine Modulation (CKM: Interferon Alpha 2b, Rintatolimod and Celecoxib) in Melanoma Patients With Primary PD-1/PD-L1 Resistance

This phase II trial studies how well polarized dendritic cell (aDC1) based therapy, interferon alpha-2, rintatolimod, and celecoxib work together in treating patients with HLA-A2 positive (+) melanoma that has not responded to previous treatment (refractory). The aDC1 cell-based treatment contains white blood cells (dendritic cells or DCs) that stimulates the immune system. Interferon alpha-2 can improve the body's natural response to infections and other diseases. It can also interfere with the division of cancer cells and slow tumor growth. Rintalolimid may stimulate the immune system. Celecoxib is a drug that reduces pain. This study is being done to find out if the combination of the study cell-based treatment (aDC1 dendritic cells) and interferon alpha-2, rintatolimod, and celecoxib can prevent the growth and/or progression of melanoma.

开始日期2024-11-20

申办/合作机构

Roswell Park Comprehensive Cancer Center

[+1]

NCT04379518 / Suspended临床1/2期IIT

Phase 1/2A Study of Rintatolimod and IFN Alpha Regimen in Cancer Patients With COVID-19

This phase I/IIa trial studies the best dose and side effects of rintatolimod and interferon (IFN) alpha-2b in treating cancer patients with COVID-19 infection. Interferon alpha is a protein important for defense against viruses. It activates immune responses that help to clear viral infection. Rintatolimod is double stranded ribonucleic acid (RNA) designed to mimic viral infection by stimulating immune pathways that are normally activated during viral infection. Giving rintatolimod and interferon alpha-2b may activate the immune system to limit the replication and spread of the virus.

开始日期2020-11-17

申办/合作机构

Roswell Park Comprehensive Cancer Center

[+1]

NCT04081389 / Completed临床1期IIT

Phase I Clinical Trial Assessing the Combination of Chemokine Modulation With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

This phase I trial studies how well chemokine modulation therapy and standard chemotherapy given before surgery work in treating patients with early stage triple negative breast cancer. Chemokine modulation therapy, including celecoxib, recombinant interferon alfa-2b, and rintatolimod, may stimulate the immune system and stop tumor cells from growing. Drugs used in standard chemotherapy, such as paclitaxel, doxorubicin, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemokine modulation therapy together with standard chemotherapy may work better than giving either therapy alone in treating patients with triple negative breast cancer.

开始日期2019-12-06

申办/合作机构

Roswell Park Comprehensive Cancer Center

[+1]

100 项与干扰素α-2b生物类似药(Center For Genetic Engineering And Biotechnology) 相关的临床结果

登录后查看更多信息

100 项与干扰素α-2b生物类似药(Center For Genetic Engineering And Biotechnology) 相关的转化医学

登录后查看更多信息

100 项与干扰素α-2b生物类似药(Center For Genetic Engineering And Biotechnology) 相关的专利（医药）

登录后查看更多信息

4

项与干扰素α-2b生物类似药(Center For Genetic Engineering And Biotechnology) 相关的文献（医药）

2020-12-01·Journal of Interferon & Cytokine Research

Therapeutic Effectiveness of Interferon Alpha 2b Treatment for COVID-19 Patient Recovery

Article

作者: González, Daniel ; Pereda, Ricardo ; Betancourt, Julio Roberto ; Rivero, Hubert Blas ; Nodarse, Hugo ; Domínguez, Rodolfo Emilio ; Mezquia, Natacha ; Lopez, Lissette Del Rosario ; Venegas, Rafael ; Rivero, Juan Carlos ; Pérez, Albadio

A previous report on 814 patients who were coronavirus disease 2019 (COVID-19) positive provided preliminary therapeutic efficacy evidence with interferon-α2b (IFN-α2b) in Cuba, from March 11 to April 14, 2020. This study re-evaluates the effectiveness of IFN-α2b during the period from March 11 to June 17, 2020. Patients received a combination of oral antivirals (lopinavir/ritonavir and chloroquine) with intramuscular or subcutaneous administration of IFN-α2b. The primary endpoint was the proportion of patients discharged from the hospital; the secondary endpoint was the case fatality rate, and several outcomes related to time variables were also evaluated. From March 11 to June 17, 2,295 patients had been confirmed to be severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positive in Cuba, 2,165 were treated with Heberon^® Alpha R, and 130 received the approved protocol without IFN. The proportion of fully recovered patients was higher in the IFN-treated compared with the non-IFN-treated group. Prior IFN treatment decreases the likelihood of intensive care and increases the survival after severe or critical diseases. Benefits of IFN were significantly supported by time variables analyzed. This second report confirmed our preliminary evidence about the therapeutic effectiveness of IFN-α2b in SARS-CoV-2 infection and postulated Heberon Alpha R as the main component within antiviral drugs used in the Cuban protocol COVID-19.

2020-09-01·Journal of Interferon & Cytokine Research4区 · 医学

Therapeutic Effectiveness of Interferon-α2b Against COVID-19: The Cuban Experience

4区 · 医学

Article

作者: González, Daniel ; López, Lissette Del Rosario ; Pereda, Ricardo ; Betancourt, Julio Roberto ; Rivero, Hubert Blas ; Domínguez, Rodolfo Emilio ; Mezquia, Natacha ; Venegas, Rafael ; Rivero, Juan Carlos ; Pérez, Albadio

A prospective observational study was conducted for assessing the therapeutic efficacy of interferon (IFN)-α2b in patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during the first month after the coronavirus disease 2019 (COVID-19) outbreak began in Cuba. From March 11th to April 14th, 814 patients were confirmed SARS-CoV-2 positive in Cuba. Seven hundred sixty-one (93.4%) were treated with a combination of oral antivirals (lopinavir/ritonavir and chloroquine) with intramuscular administration of IFN-α2b (Heberon^® Alpha R, Center for Genetic Engineering and Biotechnology, Havana, Cuba), 3 times per week, for 2 weeks. Fifty-three patients received the approved COVID protocol without IFN treatment. The proportion of patients discharged from hospital (without clinical and radiological symptoms and nondetectable virus by real-time polymerase chain reaction) was higher in the IFN-treated compared with the non-IFN treated group (95.4% vs. 26.1%, P < 0.01). The case fatality rate (CFR) for all patients was 2.95%, and for those patients who received IFN-α2b the CFR was reduced to 0.92. Intensive care was required for 82 patients (10.1%), 42 (5.5%) had been treated with IFN. This report provides preliminary evidence for the therapeutic effectiveness of IFN-α2b for COVID-19 and suggests that the use of Heberon Alpha R may contribute to complete recovery of patients.

2004-01-01·Drugs in R & D4区 · 医学

Bioequivalence of Two Recombinant Interferon ??-2b Liquid Formulations in Healthy Male Volunteers

4区 · 医学

ArticleOA

作者: Armando Correa-Fernandez ; Jorge Ducongé ; Idrian Garcia-Garcia ; Lourdes Olivera-Ruano ; Francisco Hernandez-Bernal ; Carmen Valenzuela-Silva ; Majel Cervantes-Llano ; Joel Ferrero-Bibilonia ; Carlos Alberto Gonzalez-Delgado ; Pedro Lopez-Saura ; Ramon Soto-Hernandez

OBJECTIVEInterferon (IFN) alpha-2b is a protein with antiviral, antiproliferative and immunoregulatory properties that is approved for several clinical indications. A new liquid, albumin-free, IFNalpha-2b formulation has recently been developed. This study aimed to evaluate the equivalence of the pharmacokinetic, pharmacodynamic and safety properties of the new formulation with a reference one in healthy male volunteers.METHODSA randomised, crossover, double-blind study with a 3-week washout period was performed in which Heberon Alfa R (formulation A) and Viraferon (formulation B) were compared. A single 20 x 10(6) IU IFNalpha-2b dose was administered subcutaneously to 14 apparently healthy male subjects. Serum IFN level was measured over 48 hours by enzyme immunoassay (EIA) and by antiviral activity titration. Clinical and laboratory variables were determined, as were pharmacodynamic and safety criteria.RESULTSGroups were homogeneous with regard to all demographic and baseline variables. Pharmacokinetic comparison by EIA did not show differences between the formulations: area under the curve (AUC) 2572 versus 2561 ng x h/L, maximum plasma concentration (Cmax) 318 versus 354 ng/L, time to Cmax (tmax) 8.2 versus 8.5 h, elimination half-life (t(1/2)) 5.87 versus 6.08 h, terminal elimination rate (lambda) 0.122 versus 0.118 h(-1), and mean residence time (MRT) 10.9 versus 12.0 h for formulations A and B, respectively. The differences never reached 20%, which is the clinically significant threshold. The 90% confidence interval of the ratio between them was in all cases within the 0.8, 1.25 range. The two formulations were clinically equivalent with regard to serum IFN antiviral activity titration (0.8, 1.25 criterion) regarding their pharmacokinetic parameters. There were no significant differences with respect to the pharmacodynamic variables: serum beta2-microglobulin and temperature increase. Heart rate and blood pressure changes did not differ either. Both products provoked similar haematological count decreases and had similar safety profiles. The most frequent adverse reactions were fever, tachycardia, headache and arthralgias.CONCLUSIONThe overall analysis strongly suggests the bioequivalence of these two products.

100 项与干扰素α-2b生物类似药(Center For Genetic Engineering And Biotechnology) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	L03AB05	-

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
病毒感染	古巴	-	2000-12-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03403634 (CTgov)	临床2期	肝转移 \| 复发性结直肠癌 \| 结直肠癌	19	Laboratory Biomarker Analysis+Intron A+Heberon Alfa+Urifron+Rintatolimod+Celecoxib	鬱糧壓糧築觸餘製艱鑰(觸窪網顧襯築膚鏇糧簾) = 衊鏇顧鹹獵壓製艱鏇壓獵艱壓範醖獵窪獵鏇鑰 (鑰夢顧觸構遞淵鏇獵積, 鑰鹽簾鬱積淵選製簾鏇 ~ 廠膚製夢夢醖糧獵鑰範) 更多	-	2022-03-02
NCT01460875 (CTgov)	N/A	皮肤黑色素瘤	34	laboratory biomarker analysis+Intron A+Heberon Alfa	糧遞膚衊蓋膚鬱蓋襯積(窪衊夢齋壓獵襯餘艱窪) = 繭遞齋簾餘齋製積製壓觸鹽膚構艱積顧鬱醖顧 (艱繭廠壓網觸簾齋齋齋, 積鏇膚窪蓋鬱構膚膚構 ~ 夢願願鑰網壓齋齋顧鑰) 更多	-	2018-11-02
NCT00126594 (CTgov)	临床2期	转移性肾细胞癌	80	Laboratory Biomarker Analysis+Sorafenib Tosylate (Sorafenib Tosylate)	壓醖壓網鹽觸鹽糧齋願(淵廠廠繭製衊獵網廠範) = 觸網蓋鏇簾觸簾觸鹽膚鹽願鬱鑰憲鬱構淵鬱餘 (夢廠淵築餘觸網築壓醖, 範艱艱醖繭衊淵鬱鏇襯 ~ 蓋窪選膚觸餘廠餘顧築) 更多	-	2016-09-16
NCT00126594 (CTgov)	临床2期	转移性肾细胞癌	80	Laboratory Biomarker Analysis+Sch 30500+Heberon Alfa+Urifron+Sorafenib Tosylate (Sorafenib Tosylate, Recombinant Interferon Alfa-2b)	壓醖壓網鹽觸鹽糧齋願(淵廠廠繭製衊獵網廠範) = 鏇選繭選鑰築艱壓膚壓鹽願鬱鑰憲鬱構淵鬱餘 (夢廠淵築餘觸網築壓醖, 壓製蓋觸鹽糧選蓋壓觸 ~ 顧襯繭糧鹹範蓋壓遞選) 更多	-	2016-09-16